2023 World Conference on Lung Cancer (Posters)-P2.02. Neoadjuvant Immunotherapy Related Pneumonitis in Non-Small Cell Lung Cancer Patients: Incidence, Risk Factors, and Management

P2.02. Neoadjuvant Immunotherapy Related Pneumonitis in Non-Small Cell Lung Cancer Patients: Incidence, Risk Factors, and Management - PDF(Slides)

Back to course

Pdf Summary

This document is a research poster presentation about the incidence, risk factors, and management of neoadjuvant immunotherapy related pneumonitis (CIP) in non-small cell lung cancer (NSCLC) patients. Neoadjuvant immunotherapy involves administering immune therapy before surgery to shrink the tumor and stimulate the immune system to fight cancer cells.<br /><br />The study analyzed the medical records of 97 NSCLC patients who underwent neoadjuvant treatment with checkpoint inhibitors. CIP is an immune-related adverse event that occurs when the immune system attacks lung tissue. The symptoms of CIP can range from mild to severe, including cough, shortness of breath, chest pain, and fever.<br /><br />The management of CIP is challenging and typically involves discontinuing the checkpoint inhibitor and administering corticosteroids. The optimal dose and duration of corticosteroid therapy for CIP are not well established, and additional immunosuppressive therapy may be necessary in severe cases.<br /><br />The study found that 24.7% of patients developed CIP, with a median onset time of 50 days. Patients with CIP had a longer duration of immunotherapy and higher baseline C-reactive protein levels compared to those without CIP. Five patients required systemic corticosteroid therapy, and two developed severe respiratory failure requiring mechanical ventilation.<br /><br />The study highlights the importance of investigating the incidence, clinical characteristics, and management of CIP in NSCLC patients undergoing neoadjuvant immunotherapy. Understanding the risks and developing effective strategies for managing CIP can improve patient outcomes.<br /><br />Overall, the study provides insights into the use of neoadjuvant checkpoint inhibitors in NSCLC patients and adds to the existing knowledge about the incidence, risk factors, and management of CIP. The findings may inform clinical decision-making and help improve patient outcomes in this treatment approach.

Asset Subtitle

Long Jiang

Meta Tag

Speaker Long Jiang

Topic Local-Regional NSCLC: Toxicities of Multimodality Therapy

Keywords

neoadjuvant immunotherapy

pneumonitis

non-small cell lung cancer

NSCLC

incidence

risk factors

management

checkpoint inhibitors

immune-related adverse event

C-reactive protein levels